心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JAMA：固定剂量复合用药策略可提高心血管疾病患者依从性

2013-09-11 箫砚 dxy

FDC心血管
关注

此前一些试验证明，固定剂量复合用药（FDC)可改善心血管疾病患者依从性。为评估阿司匹林、他汀类药物、以及2种降血压药物的FDC用药策略与传统用药策略相比，是否可以改善患者依从性并可改善心血管疾病高危因素（收缩压及LDL-C），研究人员进行了UMPIRE研究。研究结果近期发表在JAMA杂志上。【原文阅读】UMPIRE研究共纳入来自印度和欧洲的2004名心血管疾病或心血管疾病高危患者。所有患者被按照1

此前一些试验证明，固定剂量复合用药（FDC)可改善心血管疾病患者依从性。为评估阿司匹林、他汀类药物、以及2种降血压药物的FDC用药策略与传统用药策略相比，是否可以改善患者依从性并可改善心血管疾病高危因素（收缩压及LDL-C），研究人员进行了UMPIRE研究。研究结果近期发表在JAMA杂志上。【原文阅读】

UMPIRE研究共纳入来自印度和欧洲的2004名心血管疾病或心血管疾病高危患者。所有患者被按照1:1的比例被随机分配成两组，一组为FDC用药策略，一组接受常规用药。FDC用药策略组别又分两组，一组接受75mg阿司匹林、40mg辛伐他汀、10mg赖诺普利、50mg阿替洛尔或，一组接受75mg阿司匹林、40mg辛伐他汀、10mg赖诺普利、12.5mg氢氯噻嗪。研究主要终点为患者用药依从性以及SBP与LDL-C与基础值相比的变化。

在这项研究中，2004名受试者的初始平均血压为137/78mm Hg,LDL-C初始平均值为91.5 mg/dL。本次研究平均随访时间为15个月。结果显示，FDC组患者依从性高于常规治疗组别，FDC组SBP平均下降幅度为2.6mmHg，LDL-C平均下降幅度为4.2mg/dl。两组之间严重心血管不良事件发生率之间没有显著差异。

这项研究表明，对于CVD患者及CVD高危人群，对治疗高血压、胆固醇以及血小板等药物采用FDC用药策略，患者依从性要优于传统用药策略，且FDC用药策略可改善患者SBP 和 LDL-C，这一点统计学意义显著。

原文阅读

Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, Grobbee DE, Bots ML, Reddy KS, Cidambi R, Bompoint S, Billot L, Rodgers A; UMPIRE Collaborative Group.Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.JAMA. 2013 Sep 4;310(9):918-29. doi: 10.1001/jama.2013.277064.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1798926, encodeId=b5c71e98926dc, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jul 13 20:32:00 CST 2014, time=2014-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319242, encodeId=ea5b1319242a0, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Sep 13 00:32:00 CST 2013, time=2013-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497800, encodeId=102a149e80067, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Sep 13 00:32:00 CST 2013, time=2013-09-13, status=1, ipAttribution=)]
    2014-07-13 hmwwww

    #疾病患者#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1798926, encodeId=b5c71e98926dc, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jul 13 20:32:00 CST 2014, time=2014-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319242, encodeId=ea5b1319242a0, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Sep 13 00:32:00 CST 2013, time=2013-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497800, encodeId=102a149e80067, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Sep 13 00:32:00 CST 2013, time=2013-09-13, status=1, ipAttribution=)]
    2013-09-13 fyxzlh

    #依从性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1798926, encodeId=b5c71e98926dc, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jul 13 20:32:00 CST 2014, time=2014-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319242, encodeId=ea5b1319242a0, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Sep 13 00:32:00 CST 2013, time=2013-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497800, encodeId=102a149e80067, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Sep 13 00:32:00 CST 2013, time=2013-09-13, status=1, ipAttribution=)]
    2013-09-13 andy2090

    #血管疾病#

    0